Statins and neuroprotection: A prescription to move the field forward

Annals of the New York Academy of Sciences

Volumn 1199, Issue , 2010, Pages 69-76

  Wood, W Gibson ^a   Eckert, Gunter P ^b   Igbavboa, Urule ^a   Müller, Walter E ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; Cerebrovascular disease; Cholesterol; HMG CoA reductase; Isoprenoids; Neurodegeneration; Nneuroprotection; Statins; Stroke

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

BRAIN FUNCTION; CELL DEATH; CONFERENCE PAPER; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG UPTAKE; HUMAN; HYDROPHILICITY; LIPOPHILICITY; NEUROPROTECTION; NONHUMAN; PRESCRIPTION;

ANIMALIA;

EID: 77953971007     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05359.x     Document Type: Conference Paper

References (56)

1. Tobert, J.A. 2003. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. 2: 517-526.
2. Law, M.R. et al. 2003. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review andmeta-analysis. Br.Med. J. 326: 1-7.
3. Nassief, A. & J.D. Marsh. 2008. Statin therapy for stroke prevention. Stroke 39: 1042-1048.
4. Wahner, A.D. et al. 2008. Statin use and the risk of Parkinson disease. Neurology 70: 1418-1422.
5. Eckert, G.P. et al. 2005. Statins: drugs for Alzheimer's disease? J. Neural Transm. 112: 1057-1071.
6. Neuhaus, O. & H.P. Hartung. 2007. Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis. Expert. Rev. Neurother. 7: 547-556.
7. Tapia-Perez, J.H. et al. 2008. Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). J. Neurotrauma. 25: 1011-1017.
8. Stepien, K. et al. 2005. Neuroprotective properties of statins. Pharmacol. Rep. 57: 561-569.
9. Eckert, G.P. et al. 2007. Cholesterol-lowering drugs and Alzheimer's disease. Future Lipidol. 2: 423-432.
10. Tapia-Perez, H. et al. 2007. Statins and brain protection mechanisms. Revista de Neurologia 45: 359-364.
11. Farooqui, A.A. et al. 2007. Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans. Brain Res. Rev. 56: 443-471.
12. Orr, J.D. 2008. Statins in the spectrum of neurologic disease. Curr. Atheroscler. Rep. 10: 11-18.
13. Botti, R.E. et al. 1991. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin. Neuropharmacol. 14: 256-261.
14. Ishigami, M. et al. 2001. A comparison of the effects of 3- hydroxy-3-methylglutaryl-coenzymeA(HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. DrugMetab. Dispos. 29: 282-288.
15. Schachter, M. 2004. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fund Clin. Pharmacol. 19: 117-125.
16. Saheki, A. et al. 1994. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm. Res. 11: 305-311.
17. Johnson-Anuna, L.N. et al. 2005. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J. Pharmacol. Exp. Ther. 312: 786-793.
18. Thelen, K.M. et al. 2006. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J. Pharmacol. Exp. Ther. 316: 1146-1152.
19. Hasegawa,M. et al. 2003. Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives. J. Pharmacol. Exp. Ther. 305: 1087-1097.
20. Takeda, M. et al. 2004. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur. J. Pharmacol. 483: 133-138.
21. Kusuhara, H. et al. 1999. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J. Biol. Chem. 274: 13675-13680.
22. Tsuji, A. et al. 1993. Transportmechanism of 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J. Pharmacol. Exp. Ther. 267: 1085-1090.
23. Jacobsen, W. et al. 2000. Lactonization is the critical first step in the disposition of the 3-hydroxy- 3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab. Dispos. 28: 1369-1378.
24. Kantola, T. et al. 1998. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin. Pharmacol. Ther. 64: 58-65.
25. Pai, H.V. et al. 2002. Differential metabolism of alprazolam by liver and brain c (P4503A) to pharmacologically active metabolite. Pharmacogenomics 2: 243-258.
26. Schinkel, A.H. 1997. The physiological function of drugtransportingP- glycoproteins. Semin. CancerBiol. 8: 161-170.
27. Bogman, K. et al. 2001. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br. J. Pharmacol. 132: 1183-1192.
28. Hirrlinger, J. et al. 2002. Expression of mRNAs of multidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurons. J. Neurochem. 82: 716-729.
29. Sun, H. et al. 2003. Drug efflux transporters in the CNS. Adv. Drug Deliv. Rev. 55: 83-105.
30. Zacco, A. et al. 2003. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J. Neurosci. 23: 11104-11111.
31. Bösel, J. et al. 2005. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J. Neurochem. 92: 1386-1398.
32. Johnson-Anuna, L.N. et al. 2007. Simvastatin protects neurons fromcytotoxicity by up-regulating Bcl-2mRNA and protein. J. Neurochem. 101: 77-86.
33. Lim, J.H. et al. 2006. Simvastatin prevents oxygen and glucose deprivation/reoxygenation-induced death of cortical neurons by reducing the production and toxicity of 4-hydroxy-2E-nonenal. J. Neurochem. 97: 140-150.
34. Domoki, F. et al. 2009. Rosuvastatin induces delayed preconditioning against oxygen-glucose deprivation in cultured cortical neurons. Am. J. Physiol. Cell Physiol. 296: C97-C105.
35. Franke, C. et al. 2007. Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiol. Dis. 25: 438-445.
36. Bucelli, R.C. et al. 2008. Statins decrease expression of the proinflammatory neuropeptides calcitonin gene-related peptide and substance P in sensory neurons. J. Pharmacol. Exp. Ther. 324: 1172-1180.
37. Michikawa, M. & K.Yanagisawa. 1999. Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death. J. Neurochem. 72: 2278-2285.
38. Tanaka,T. et al. 2000. Geranylgeranyl-pyrophosphate, an isoprenoid ofmevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl- CoA reductase inhibition. J. Neurosci. 20: 2852-2859.
39. Schulz, J.G. et al. 2004. HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. J. Neurochem. 89: 24-32.
40. Jiang, Z. et al. 2004. Lovastatin-induced up-regulation of the BH3-only protein, Bim, and cell death in glioblastoma cells. J. Neurochem. 89: 168-178.
41. März, P. et al. 2007. Statins induce differentiation and cell death in neurons and astroglia. Glia 55: 1-12.
42. Klopfleisch, S. et al. 2008. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. J. Neurosci. 28: 13609-13614.
43. Xiang, Z. & S.A. Reeves. 2009. Simvastatin induces cells death in a mouse cerebellar slice culture (CSC) model of developmental myelination. Exp. Neurol. 215: 41-47.
44. Chochina, S.V. et al. 2001. Amyloidβ-peptide1-40 increases neuronal membrane fluidity: role of cholesterol and brain region. J. Lipid Res. 42: 1292-1297.
45. Solomon, K.R. & M.R. Freeman. 2008. Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol. Metab. 19: 113-121.
46. Liao, J.K. & U. Laufs. 2004. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45: 89-118.
47. Swanson, K.M. & R.J. Hohl. 2006. Anti-cancer therapy: targeting the mevalonate pathway. Curr. Cancer Drug Targets 6: 15-37.
48. Cole, S.L.&R.Vassar. 2006. Isoprenoids and Alzheimer's disease: a complex relationship. Neurobiol. Dis. 22: 209-222.
49. Wood, W.G. et al. 2007. Cholesterol-a Janus faced molecule in the central nervous system. In Handbook of Neurochemistry and Molecular Neurobiology-Neural Membranes and Transport . A Lajtha & M.E.A. Reith, Eds.: 151-170. Springer. New York.
50. Basso, A.D. et al. 2006. Farnesyl transferase inhibitors. J. Lipid Res. 47: 15-31.
51. Mc Taggart, S.J. 2006. Isoprenylated proteins. Cell Mol. Life Sci. 63: 255-267.
52. Cole, S.L. 2005. Statins cause intracellular accumulation of amyloid precursor protein.-secretase-cleaved fragments, and amyloid-peptide via an isoprenoiddependent mechanism. J. Biol. Chem. 280: 18755-18770.
53. Ostrowski, S.M. et al. 2007. Statins reduce amyloid- production through inhibition of protein isoprenylation. J. Biol. Chem. 282: 26832-26844.
54. Tong,H. et al. 2008. Quantitative determination of farnesyl and geranylgeranyl diphosphate levels in mammalian tissue. Anal. Biochem. 378: 138-143.
55. Hooff, G.P. et al. 2008. Isoprenoid quantitation in human brain tissue: a validated HPLC-fluorescence detection method for endogenous farnesyl- (FPP) and geranylgeranylpyrophosphate (GGPP). Anal. Bioanal. Chem. 392: 673-680.
56. Tong, H. et al. 2005. Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Anal. Biochem. 336: 51-59.